LumiraDx rises on FDA clearance for test to differentiate between flu and COVID

LumiraDx

06/02/2023 14:29

** Shares of diagnostics company LumiraDx Ltd  LMDX.O  rise
10.8% to $1.33 before the bell
    ** FDA grants emergency use authorization to co's test to
identify and differentiate individuals suspected of respiratory
viral (RSV) infections due to flu from those consistent with
COVID
    ** Clinical signs and symptoms of RSV infection due to
SARS-CoV-2 and influenza can be similar, thus need to be
correctly identified - LMDX
    ** The test also got validated by the UK Health Security
Agency under the Coronavirus Test Device Approvals process
    ** Co to begin commercialization of the test in the U.S. and
U.K
    ** Stock has declined 86% in last 12 months
 (Reporting by Aditya Samal)
 ((Aditya.Samal@thomsonreuters.com;))